Medtronic commences pivotal trial for Next-Generation CGM sensor
Category: #health  By Mateen Dalal  Date: 2019-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic commences pivotal trial for Next-Generation CGM sensor

Next-generation Guardian CGM is designed to lower sensor calibrations, improve and refine the accuracy and the overall performance of the system

World’s largest company for medical devices, Medtronic recently announced that it has started a pivotal trial of the company’s next-generation Guardian (TM) continuous glucose monitoring (CGM) sensor.

It has specifically been designed to lower sensor calibrations, improve and refine the accuracy and the overall performance of the system, sources familiar with the matter informed.

According to sources, over the span of seven days the next-generation CGM Sensor, in around 460 participants aged from two to 80 years old diagnosed with type one and two diabetes, shall be studied under the prospective trial. Sensor wear locations along with days and times when the testing will be done will be assigned to the participants randomly.

Medtronic’s Diabetes Group Research and Development vice president, Ali Dianaty believes that it is essential for the calibration to take place on the first day of wear because it improves the performance since day one.

Dianaty adds that research has depicted the performance for day one is crucial in the sense that it keeps the patients safe and protected in Auto Mode, or hybrid close loop which provides maximum Time in Range on insulin therapy for patients, as previously learned from real world experiences.

The vice president expressed his excitement over the next-generation CGM sensor because of its design, that needs calibration done on its first day which in turn results in 95% reduction of fingersticks as compared to existing CGM.

Emory University’s clinical associate professor, Dr. Bruce Bode, called the trial a positive step towards improving the experience with hybrid close loop systems of Medtronic integrated with sensors that primarily focus on the experience a patient gets.

Dr. Bode said the advancements are informed with the vigorous use of Medtronic therapies in the real world. It lays an emphasis on making sure that apart from delivering the best results, the technologies focuses mainly on ease of use.

Source Credit- http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2400976

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
By Mateen Dalal

Hyundai Motor Company identifies the significance and impact of automobiles, and strives to fulfill its goals by creating new and advanced vehicles that addresses all the vital issues faced by drivers. The automobile giant has effectively become...

TransPerfect expands its portfolio by acquiring Sublime Subtitling
TransPerfect expands its portfolio by acquiring Sublime Subtitling
By Mateen Dalal

With decades of hard work and hands-on experience, TransPerfect has managed to become one of the largest global providers of technology and language solutions for companies worldwide. With over 5,000 global organizations employing its GlobalLink®...

Altran to launch a Digital Therapeutics Innovation Center in Boston
Altran to launch a Digital Therapeutics Innovation Center in Boston
By Mateen Dalal

Digital therapeutics are evidence-based interventions conducted by advanced software programs to manage, treat or prevent clinical disorders. Its adoption has augmented the whole medical industry, making it simpler for practitioner to ...